Organon & Co. (OGN) shares surged approximately 25% in early trading Friday following a report from The Economic Times indicating that India-based Sun Pharmaceutical Industries has submitted a binding, all-cash acquisition proposal valued at around $13 billion. The deal, if confirmed, would place the U.S. women's health drugmaker firmly in play, intensifying a takeover contest that already includes private equity firm EQT and Germany's Grünenthal.
According to the report, Sun Pharma's offer is fully financed with $12 billion in commitments from JPMorgan, MUFG, and Citigroup, and would not involve any stock component for Organon shareholders. The bid significantly exceeds Organon's current equity market capitalization of roughly $2.8 billion, reflecting a substantial premium that underscores the strategic appeal of the company's product portfolio.
Market Reaction and Investor Sentiment
While Organon shares rallied to around $10.75 in New York, Sun Pharma's stock fell more than 3% in Mumbai trading, signaling investor unease about the potential acquisition. BNP Paribas analyst Navann Ty commented that while Organon's long-term positioning remains strong, a Sun Pharma deal could be viewed as imprudent capital allocation given the increased leverage it would entail.
Neither Organon nor Sun Pharma has officially confirmed the transaction. Notably, Sun Pharma told Indian exchanges on April 10 that an earlier report about a $12 billion bid was speculative and that no material event required disclosure under listing rules.
Organon's Financial Profile
Organon, headquartered in Jersey City, New Jersey, reported 2025 revenue of $6.216 billion and adjusted EBITDA of $1.907 billion. The company ended the year with $8.64 billion in debt. For 2026, management has guided for roughly flat revenue of about $6.2 billion and adjusted EBITDA of approximately $1.9 billion. The company is scheduled to report first-quarter 2026 results on May 7.
The company's portfolio spans women's health, established medicines, and biosimilars, including the contraceptive implant Nexplanon, fertility treatments, Vtama cream, and biosimilars in immunology and oncology. This diversified product base is a key attraction for potential acquirers.
Valuation and Deal Risks
At the previously reported $12 billion valuation, Business Today cited ICICI Direct estimates that Organon would be valued at about two times expected 2026 sales and six times EBITDA. Salil Kallianpur, a pharma analyst, noted that Sun's higher bid suggests this is more than a strategic acquisition, but warned that paying a premium reduces the margin for error.
Several risks remain. The deal may not materialize, a rival bidder could emerge with a higher offer, or Sun Pharma could withdraw if the debt burden proves too onerous. Additionally, Organon carries governance concerns: Reuters reported in October that former CEO Kevin Ali resigned after an internal probe found improper sales practices related to Nexplanon wholesaler purchases, though the company stated the findings did not require a financial restatement.
For now, Organon stock is trading less like a slow-growth drugmaker and more like a takeover target. The next move hinges on whether a formal offer is made, whether competing bidders stay in the race, and whether buyers are willing to assume nearly $9 billion in debt for a women's health and biosimilars platform.
